Financial Performance - Revenue for Q1 2023 reached ¥1,957,286,746.09, an increase of 15.61% compared to ¥1,693,054,812.68 in the same period last year[4] - Net profit attributable to shareholders decreased by 39.85% to ¥44,586,378.55 from ¥74,122,394.99 year-on-year[4] - Operating profit decreased to CNY 89,342,413.99, a decline of 29% from CNY 125,781,271.03 in Q1 2022[17] - The company reported a total comprehensive income of CNY 61,039,819.41, compared to CNY 76,597,566.88 in the same quarter last year[18] - Earnings per share (EPS) for Q1 2023 was CNY 0.05, down from CNY 0.08 in Q1 2022[18] Cash Flow - Net cash flow from operating activities fell by 50.01% to ¥232,773,328.32, down from ¥465,654,770.34 in the previous year[4] - Cash flow from operating activities was CNY 1,879,602,203.12, down 19.7% from CNY 2,339,136,126.31 in Q1 2022[20] - Total cash inflow from operating activities was ¥2,346,423,674.88, while cash outflow was ¥2,113,650,346.56, resulting in a net increase of ¥232,773,328.32[21] - The company reported a total cash outflow for operating activities of ¥2,113,650,346.56, which is an increase from ¥2,055,853,904.00 in Q1 2022[21] - The ending balance of cash and cash equivalents was ¥567,822,192.58, compared to ¥733,861,728.76 at the end of Q1 2022[21] Assets and Liabilities - Total assets decreased by 2.15% to ¥14,686,639,932.71 from ¥15,008,660,120.73 at the end of the previous year[4] - Total current assets amount to ¥6,022,050,762.92, a decrease from ¥6,388,619,191.46 at the beginning of the year[15] - Total liabilities amounted to CNY 7,339,409,343.81, a decrease of 5.8% from CNY 7,790,727,890.92 at the end of the previous period[17] - Long-term borrowings increased by 37.65% to ¥2,086,153,500.00, indicating additional financing activities[9] - Short-term borrowings decreased to ¥1,273,892,681.12 from ¥1,702,001,075.05[15] Research and Development - Research and development expenses increased by 41.60% to ¥103,353,730.08, reflecting higher investment in R&D[9] - Research and development expenses increased to CNY 103,353,730.08, up 41.4% from CNY 72,988,361.85 in the previous year[17] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 20,557[11] - The largest shareholder, Mu Jinxiang, holds 25.40% of shares, totaling 234,535,853 shares[11] Other Income and Expenses - The company received government subsidies amounting to ¥4,011,991.93 during the quarter[6] - Other comprehensive income rose by 72.81% to ¥8,233,266.17, primarily due to foreign currency translation differences[9] - The company received tax refunds amounting to CNY 141,487,812.54 during the quarter, compared to CNY 158,296,714.21 in Q1 2022[20] - The company received ¥19,768,051.85 from other investment activities, a significant decrease from ¥98,074,349.16 in the previous year[21] - The company paid ¥783,038,860.00 in debt repayments during the quarter, compared to ¥610,598,620.00 in Q1 2022[21]

Financial Performance - The company's operating revenue for 2022 was CNY 7,865,465,550.37, representing a 19.41% increase compared to CNY 6,586,780,685.31 in 2021[21]. - The net profit attributable to shareholders for 2022 was CNY 696,838,439.53, a significant increase of 120.93% from CNY 315,405,020.68 in 2021[21]. - The net profit after deducting non-recurring gains and losses was CNY 507,731,875.98, up 76.21% from CNY 288,143,739.71 in 2021[21]. - The basic earnings per share for 2022 was CNY 0.75, a 120.59% increase compared to CNY 0.34 in 2021[21]. - The total assets at the end of 2022 were CNY 15,008,660,120.73, an 18.72% increase from CNY 12,641,780,515.38 at the end of 2021[21]. - The net assets attributable to shareholders at the end of 2022 were CNY 6,951,263,314.13, a 10.32% increase from CNY 6,301,198,272.75 at the end of 2021[21]. - The company reported a net cash flow from operating activities of CNY 638,760,811.35, a decrease of 13.42% from CNY 737,788,383.17 in 2021[21]. - The total profit for 2022 was 94,443.92 million CNY, reflecting a significant increase of 126.57% compared to the previous year, while net profit attributable to shareholders reached 69,683.84 million CNY, up by 120.93%[69]. - The total operating revenue for 2022 reached ¥7,865,465,550.37, representing a year-on-year increase of 19.41% compared to ¥6,586,780,685.31 in 2021[93]. - The main business revenue accounted for ¥7,856,295,870.66, which is 99.88% of total revenue, with a year-on-year growth of 19.85%[93]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 1 RMB per 10 shares to all shareholders, with no bonus shares issued[5]. - The total distributable profit for shareholders was 2,266,488,377.88 CNY, with cash dividends accounting for 100% of the profit distribution[177]. - The cash dividend distribution plan requires approval from the annual general meeting and must be implemented by the board within two months[178]. Research and Development - The company emphasizes its focus on research and development of new products and technologies to enhance market competitiveness[12]. - The company is actively involved in the development and collaboration of innovative drugs, with a focus on clinical phase II and III pipeline products[37]. - The company has established a new R&D service base in 2022, increasing its investment in research and development, particularly in areas like PROTAC and Linker technologies[56]. - R&D investment increased by 24.47% to ¥394,713,816.88 in 2022, representing 5.02% of total revenue[108]. - The number of R&D personnel rose by 7.02% to 777, with a notable increase in master's degree holders by 17.69% to 153[108]. Market and Industry Trends - The global agricultural market size in 2022 was estimated to reach USD 78 billion, with a growth rate of over 5%[30]. - The global pharmaceutical R&D investment is projected to grow from $243.7 billion in 2022 to $328.8 billion by 2026, with a compound annual growth rate (CAGR) of approximately 7.8%[32]. - The global CDMO market size increased from $39.4 billion in 2017 to $63.2 billion in 2021, with a CAGR of 12.5%, and is expected to reach $124.3 billion by 2025 and $231.0 billion by 2030[32]. - The demand for new plant protection products is increasing due to traditional varieties' resistance management and product iteration needs[30]. - The company is focusing on developing high-efficiency, low-toxicity, and environmentally friendly products in response to the global trend of reducing chemical pesticide usage[30]. Operational Efficiency and Sustainability - The report indicates a commitment to improving operational efficiency and sustainability practices within the company[12]. - The company has committed to maintaining compliance with safety, health, environment, and quality standards in its operations[12]. - The company has established a comprehensive management system integrating safety, health, environment, and quality (SHEQ&C), enhancing its competitive edge in safety and environmental protection[65]. - The company has implemented a business continuity plan (BCP) to manage risks associated with global economic downturns, ensuring operational resilience[87]. - The company is focusing on enhancing its core competitiveness in environmental protection and production through improved waste management technologies[91]. Governance and Compliance - The company has established a robust governance structure in compliance with relevant laws and regulations, ensuring independent operations and effective internal controls[150]. - The board of directors consists of seven members, including three independent directors, meeting legal requirements and ensuring diverse expertise[151]. - The company has implemented a stock incentive plan to align the interests of management and core employees with those of shareholders, promoting long-term stability and growth[152]. - The company maintains complete independence from its controlling shareholder, with no reliance on any related parties for business operations[153]. - The company has established a comprehensive compliance evaluation system for environmental protection[189]. Environmental Compliance - The company has maintained compliance with all discharge limits, indicating effective pollution control measures[194]. - The company reported a total COD emission of 44.36 tons per year, with a concentration of 319.47 mg/L, which is below the regulatory limit of 500 mg/L[192]. - The company achieved a VOC emission level of 17.86 tons per year, with a concentration of 24.17 mg/m³, which is below the limit of 60 mg/m³[192]. - The company is committed to maintaining compliance with environmental standards and reducing emissions through ongoing monitoring and improvements[192]. - The company has invested significantly in environmental protection measures, aligning with its commitment to sustainable development[200]. Future Outlook and Strategic Initiatives - The company aims for a revenue growth of no less than 10% in its industrial business for 2023 compared to 2022, contingent on macroeconomic conditions[133]. - The company plans to enhance collaboration with key customers and expand market development while ensuring stable supply and operational efficiency[134]. - The company is actively exploring potential mergers and acquisitions to bolster its market position and expand its product offerings[160]. - The company provided a positive outlook for 2023, projecting a revenue growth of 10% to 12%[146]. - The company is investing 300 million RMB in R&D for new technologies and product development[146].

Group 1: Event Details - The investor reception day is scheduled for May 18, 2023, from 3:30 PM to 5:30 PM [2] - The event will take place at Huangyan Yaoda Hotel Conference Room, No. 3, Century Avenue, Huangyan District, Taizhou City, Zhejiang Province [2] - Investors must register for the event by contacting the company's securities department between May 11, 2023, 9:00 AM - 11:00 AM and 2:00 PM - 4:00 PM [2] Group 2: Company Representatives - The event will be attended by key company personnel including Chairwoman and CEO Wang Ping, Vice Chairman Peng Yinshi, and other senior executives [2] - Adjustments to the list of attendees may occur due to special circumstances [2] Group 3: Participation Requirements - Individual investors must bring original and photocopies of their personal ID and shareholder card; institutional investors must provide relevant proof documents [2] - The company will verify and archive these documents for regulatory review [2] Group 4: Confidentiality and Efficiency - Investors are required to sign a confidentiality commitment as per Shenzhen Stock Exchange regulations [3] - To enhance reception efficiency, investors are encouraged to submit questions in advance via phone or email [3]

证券代码：002250 证券简称：联化科技 公告编号：2023-018 联化科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 （问题征集专题页面二维码） 特此公告。 联化科技股份有限公司董事会 二〇二三年四月二十二日 出席本次说明会的人员有：公司董事长兼总裁王萍女士、高级副总裁兼董事 会秘书陈飞彪先生、财务总监薛云轩先生和独立董事俞寿云先生等。 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2023年4月 27日（星期四）15:00前访问https://ir.p5w.net/zj/，或扫描下方二维码，进入问题 征集专题页面。公司将在2022年度业绩说明会上，对投资者普遍关注的问题进行 回答。 欢迎广大投资者积极参与本次网上说明会。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 联化科技股份有限公司（以下简称"公司"）定于2023年4月28日（星期五） 15:00-17:00在全景网举办2022年度业绩说明会，本次年度业绩说明会将采用网络 远程的方式举行，投资者 ...

Group 1: Investor Relations Activities - The investor relations activity was a targeted research event held on January 31, 2023, at the company's Shanghai office [1] - Participants included representatives from various financial institutions such as Tianfeng Securities and Zhongyin Securities [1] Group 2: Agricultural Protection Business - The new production capacity for the agricultural protection business is primarily located in Shandong and the UK [1] - The Jiangsu base's operational performance in 2022 was positively impacted by the global increase in agricultural product prices due to the Russia-Ukraine conflict, resulting in high utilization rates and good overall performance [1] Group 3: Pharmaceutical Projects - The pharmaceutical validation projects are progressing as planned, with some projects already completed and new validation projects being received [1] - Successful completion of these projects is expected to support growth in the pharmaceutical business in the coming years [1] Group 4: CRO Business Development - The company is expanding its CRO (Contract Research Organization) business to better meet customer needs and provide one-stop services [2] - The CRO laboratory in Shanghai is nearing completion, and the company is actively engaging with clients to explore business opportunities [2] Group 5: CDMO Business Outlook - The global agricultural terminal product market is valued at over $60 billion, with an annual growth rate of approximately 3%-5% [2] - The company focuses on serving leading agricultural enterprises and is exploring new areas such as soil health and biopesticides to ensure sustainable growth [2] Group 6: New Energy Business Development - The company has been focused on chemical synthesis and sees potential in the electronic chemicals sector as part of its future development strategy [2] - The battery chemicals project at the subsidiary Dezhou Lianhua is progressing according to plan, with installation and commissioning underway [2]

Group 1: Company Strategy and Development - The company will maintain a strategic focus on the fine chemical industry, emphasizing organic synthesis capabilities and enhancing customized services and proprietary products [1] - The company aims to promote healthy development through alliances and strategic partnerships [1] Group 2: Production and Project Updates - The Taizhou Lianhua's three fundraising projects are in normal trial production, with plans for a pilot workshop and multifunctional production workshop to commence construction, expected to be operational in the second half of 2015 [1] - The first project at Yancheng Lianhua is undergoing approval processes prior to trial production [1] - The new projects at Dezhou Lianhua are progressing, with a goal to launch three products by the end of 2014 [1] Group 3: Financial Performance and Product Insights - In 2013, the main source of new revenue and profit for Jiangsu Lianhua came from fundraising projects that commenced production that year [2] - Approximately 80% of the company's industrial revenue currently comes from pesticide intermediates, with plans to gradually increase the share of pharmaceutical intermediates in the future [2] - The company anticipates that pesticide business revenue will continue to grow, maintaining it as the primary income source for at least the next three years [2] Group 4: Environmental Investments and Challenges - The company invested over 100 million yuan in environmental facilities in 2013, which has impacted short-term performance [2] - The high environmental standards present challenges but are viewed as opportunities, with ongoing collaborations with international companies for environmental projects [2] Group 5: Sales and Revenue Generation - Taizhou Lianhua has commenced trial production, allowing for the sale of qualified products, which will generate sales revenue in the first half of the year [3]

Group 1: Project Developments - The first phase of the Texas Lianhua project has been completed on 260 acres, with the second phase currently in planning [1] - The design capacity of the phosgene facility in Texas Lianhua is set at a scale of 10,000 tons per year, with products including AKD, isocyanates, and acyl chlorides [1] - The Yancheng Lianhua pesticide project, ANBE, is currently in normal production and sales, generating expected benefits [1] Group 2: Business Improvements - The company is actively improving processes for AKD and other products, effectively reducing raw material costs and enhancing product quality [1] - The pharmaceutical intermediates business has faced slow development due to capacity, resource allocation, and market cycles, but new developments are anticipated with the completion of the Taizhou Lianhua plant and the establishment of a professional team [2] Group 3: Market Response - In response to recent significant fluctuations in the securities market, the company is formulating a plan to increase shareholding, demonstrating confidence in the capital market and the company's future [2]

Group 1: Company Development and Market Position - The company has a competitive advantage in customized chemical processing due to its strong capabilities in technology innovation, engineering construction, environmental facilities, and comprehensive management [1] - China plays a crucial role in the global chemical industry transition, with the company positioned to benefit from the outsourcing of production stages by multinational corporations [1] - The Jiangkou plant is designated as a new product incubation base, while the Taizhou plant focuses on pharmaceutical intermediates production [1][2] Group 2: Production Bases and Progress - The Taizhou plant officially commenced production in February 2015, with high-standard GMP multi-functional workshops under construction [2] - The company aims to obtain national pesticide production qualifications for its production bases in Yancheng and Jiangsu, with the first project starting trial production in March 2015 [2] - The Dezhou plant is actively developing downstream fine chemical projects to enhance production capacity [2] Group 3: Patent Expiry Impact - The company has products both under patent and nearing expiry, with varying impacts on business; generally, the price impact on original companies is significant, but the quantity impact is minimal [2] - Raw materials account for only 5%-10% of the final drug product price, indicating that price drops post-patent expiry do not primarily pressure custom service suppliers [2] Group 4: Business Strategy and Future Outlook - The trend of outsourcing pesticide and pharmaceutical intermediates in developed countries is expected to continue, providing growth opportunities for customized processing [2] - The company plans to focus on strategic alliances with major clients rather than entering formulation and terminal sales, while optimizing product structure to enhance profitability [2]

联化科技股份有限公司投资者关系活动记录表 证券代码：002250 证券简称：联化科技 编号：20150807 | --- | --- | --- | --- | --- | |-----------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------|------------------------------------------|--------| | | | | | | | 投资者关系活动类别 | □特定对象调研 | □分析师会议 | | | | | | □媒体采访 □业绩说明会 | | | | | | □新闻发布会 □路演活动 | | | | | | □现场参观 √其他（台湾机构投资者电话会议） | | | | 参与单位名称及人员 姓名 | 国泰证券 叶岦升 南山人寿 谢尚蓉 | | 练静彤 群益投信 洪玉婷 ...